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Aims. We investigate the effect of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors on long-term outcomes following percutaneous
coronary intervention (PCI) after non-ST elevation myocardial infarction (NSTEMI). Meta-analyses indicate that these agents
are associated with improved short-term outcomes. However, many trials were undertaken before the routine use of P2Y
12
inhibitors. Recent studies yield conflicting results and registry data have suggested that GP IIb/IIIa inhibitors may cause more
bleeding than what trials indicate. Methods and Results. This retrospective observational study involves 3047 patients receiving
dual-antiplatelet therapy who underwent PCI for NSTEMI. Primary outcome was all-cause mortality. Major adverse cardiac events
(MACE) were a secondary outcome. Mean follow-up was 4.6 years. Patients treated with GP IIb/IIIa inhibitors were younger with
fewer comorbidities. Although the unadjusted Kaplan-Meier analysis suggested that GP IIb/IIIa inhibitor use was associated with
improved outcomes, multivariate analysis (including propensity scoring) showed no benefit for either survival (𝑃 = 0.136) or
MACE (𝑃 = 0.614). GP IIb/IIIa inhibitor use was associated with an increased risk of major bleeding (𝑃 = 0.021). Conclusion.
Although GP IIb/IIIa inhibitor use appeared to improve outcomes after PCI for NSTEMI, patients who received GP IIb/IIIa
inhibitors tended to be at lower risk. After multivariate adjustment we observed no improvement in MACE or survival and an
increased risk of major bleeding.
1. Introduction
Percutaneous coronary intervention (PCI) has been shown
to improve clinical outcomes in non-ST elevationmyocardial
infarction (NSTEMI) [1]. These patients typically receive
multiple antiplatelet and anticoagulative therapies as per cur-
rent guidelines [2, 3]. Glycoprotein IIb/IIIa receptor inhibi-
tors are potent antiplatelet agents which have been shown
in some trials to improve outcomes in patients under-
going PCI post-NSTEMI [4–8]. Meta-analyses involving
29,570 patients withNSTEMI/UA (non-ST elevationmyocar-
dial infarction or unstable angina) have shown GP IIb/IIIa
inhibitors to be associated with a reduction in death or
nonfatal myocardial infarction at 30 days [4]. Although posi-
tive studies have suggested a potential for a 30–40% reduction
in the composite of death and MI, favouring the use of GP
IIb/IIIa inhibitors [2], these trials were carried out before the
routine use of clopidogrel or other P2Y
12
inhibitors.
Studies performed with the use of clopidogrel have
yielded conflicting results. The ISAR-REACT 2 trial [7]
demonstrated reduced short-term mortality and cardiac
events with abciximab. However, other studies such as
ACUITY Timing [9] demonstrated no benefit from early
GP IIb/IIIa inhibition to reduce the risk of major bleeds.
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Furthermore, registry data indicates that GP IIb/IIIa
inhibitors are less safe than trial data would indicate and that
their benefits may not extend to patient groups not recruited
to clinical trials [10].
Current ESC guidelines state that “it is reasonable to
combine a GP IIb/IIIa receptor inhibitor with aspirin and a
P2Y
12
inhibitor for patients with NSTE-ACS undergoing PCI
with a high risk of procedural MI and without a high risk of
bleeding” [3]. However, concerns over side effect profiles have
led to their reduced usage in current practice, especially with
the addition of newer more potent oral antiplatelet drugs.
We therefore investigated the outcome of patients treated
by PCI for NSTEMI at our institution by comparing patients
who received GP IIb/IIIa inhibitors to those who did not. We
looked at long-term mortality, inhospital MACE, and major
inhospitable bleeding complications.
2. Methods
We undertook an observational cohort study to investigate
the relationship between the use of GP IIb/IIIa inhibitors
and long-term outcomes after PCI for NSTEMI at a single
high-volume cardiac centre in East London.The study period
was from October 2003 to July 2011. During the study period
3321 patients underwent PCI for NSTEMI. Of these, 3089
(93.0%) had complete datasets and NHS numbers and were
included in the analysis. NSTEMI was diagnosed in NSTE-
ACS patients if the troponin T or I was above the reference
range of the assay used. The group of patients excluded
from the study due to incomplete data entry or absent NHS
number contained a similar proportion of GP IIb/IIIa use.
Patients with slow or no-reflow phenomenon after PCI (42
patients) were excluded as all these patients received GP
IIb/IIIa inhibition. 3047 patients remained for analysis.
Standard PCI protocol included preloading with aspirin
300mg and clopidogrel 600mg. All patients were prescribed
75mg aspirin and 75mg clopidogrel maintenance therapy.
Clopidogrel maintenance therapy was recommended for 1
year after intervention. Intravenous GP IIb/IIIa inhibitor was
administered at the operator’s discretion with the choice of
agent based on the current local guidelines, which for the
majority of patients was abciximab. Abciximab was admin-
istered as an intravenous bolus of 0.25mg/kg before/during
PCI followed by a continuous infusion of 0.125mcg/kg/min
(to a maximum of 10 𝜇g/min) for 12 hours. Eptifibatide
was administered as an intravenous bolus of 180mcg/kg
before/at the start of PCI followed by a continuous infu-
sion of 2mcg/kg/min for 12 hours following the procedure.
Tirofiban was administered as a loading dose of 400 ng/kg/
min for 30 minutes followed by a continuous infusion of
150 ng/kg/minute for 18–24 hours following the procedure.
Contraindications for GP IIb/IIIa inhibitor use included pre-
viousmajor gastrointestinal bleeding, previous haemorrhagic
stroke, chronic renal impairment, thrombocytopenia, and
concurrent oral anticoagulant use. GP IIb/IIIa inhibitor infu-
sions were stopped if there was an adverse reaction, reduction
in platelet count from baseline of >50%, or minor or major
bleeding according to the TIMI bleeding criteria. All patients
received unfractionated heparin at the time of PCI with an
initial loading dose of 85 units per kilogram, with the dose
adjusted to maintain an ACT > 300 s. All patients received
preprocedural enoxaparin at 1mg/kg subcutaneously twice
daily for up to 5 days (750mcg/kg twice daily in patients
aged above 75). Bivalirudinwas not available during the study
period.
Data were prospectively entered into a clinical PCI
database, based on the British Cardiovascular Intervention
Society (BCIS) dataset [11], at the time of the procedure.
Data collected included patient characteristics (age, prior
myocardial infarction (MI), percutaneous coronary interven-
tion (PCI), coronary artery bypass grafting (CABG), hyper-
tension, diabetes mellitus, hypercholesterolemia, peripheral
vascular disease (PVD), NYHA class, smoking status, chronic
renal impairment (CRF: creatinine > 200𝜇mol/L or on renal
replacement therapy), LV function and cardiogenic shock),
and procedure-related data (indications for PCI, target vessel,
number of diseased vessels, use of IVUS/pressure wire, and
use of drug-eluting stent and GP IIb/IIIa inhibitor).
Procedural complications and major adverse cardiac
events (MACE) were recorded prospectively. MACE were
defined as death, myocardial infarction (new pathologic Q
waves in the distribution of the treated coronary artery with
an increase of creatine kinase-MB to 2 times the reference
value or significant rise in troponin T values), and target
vessel revascularisation. Procedural complications recorded
included myocardial infarction, emergency CABG, arte-
rial complications, aortic/coronary dissection, side branch
occlusion, and arrhythmia. Procedural complications were
recorded at the time of the procedure and inhospital com-
plications were entered into the database at the time of dis-
charge. Repeated PCI rates due to target vessel revascularisa-
tion were identified from the PCI database and subsequent
surgical revascularisation rates were calculated from anal-
ysis of the surgical database. All-cause mortality data was
recorded as of 10 August 2011 and obtained via the National
Institute of Cardiovascular Outcomes Research (NICOR)
BCIS database [11]. This national database is periodically
linked to the UK Office of National Statistics and provides
live/death status of treated patients. Only patients who
had complete database records and National Health Service
unique numbers (allowing live/death status to be assessed)
were included in the analysis. Major and minor bleeding
were defined as per the TIMI bleeding criteria. Criteria for
major bleeding were any intracranial bleeding; overt bleeding
associated with a ≥5 g/dL drop in haemoglobin and/or ≥15%
absolute decrease in haematocrit; or fatal bleeding resulting
in a death within 7 days. Criteria for minor bleeding were
overt bleeding associated with 3–5 g/dL drop in haemoglobin
and/or 10–15% absolute decrease in haematocrit; occult
bleeding associated with a ≥4 g/dL drop in haemoglobin
concentration and/or ≥12% absolute decrease in haematocrit;
or any overt bleedingwhich does notmeet any of the previous
criteria and requiresmedical or surgical treatment, prolonged
hospital stay, or prompting unscheduled medical assessment
and investigation. A retrospective data quality audit of 100
randomly selected medical records established that 94.8% of
data fields, including complications, were entered correctly
into the database.
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2.1. Ethics. The data were collected as part of a national
cardiac audit and all patient identifiable fields were removed
prior to analysis.The Local Ethics Committee advised us that
formal ethical approval was not required.
2.2. Statistical Analysis. Continuous data with a normal
distribution are presented as mean ± standard deviation (SD)
and skewed data as median ± IQR. Clinical characteristics of
patients were compared using the Pearson chi-squared test
for categorical variables and Student’s 𝑡-test for continuous
variables. We calculated the Kaplan-Meier product limits for
cumulative probability of reaching an end point and used
the log rank test for evidence of a statistically significant
difference between the groups. Time was measured from
the first admission for a procedure to outcome (all-cause
mortality). The Cox regression analysis was used to estimate
hazard ratios for the effect of GP IIb/IIIa inhibitor use in age-
adjusted and fully adjusted models, based on covariates (𝑃 <
0.05) associated with the outcome. Included covariates in the
age-adjustedmodel were sex, history of hypertension, history
of hypercholesterolaemia, smoking status, previous myocar-
dial infarction, previous coronary artery bypass grafting,
previous PCI, previous stroke, history of peripheral vascular
disease, diabetes mellitus, history of chronic kidney disease,
radial approach, left anterior descending coronary artery
intervention, presence of chronic total occlusion on angiog-
raphy, presence of multivessel disease on angiography, drug-
eluting stent use, and successful angiographic result following
PCI. The proportional hazards assumption was evaluated
by examining log (−log) survival curves and additionally
was tested with Schoenfeld’s residuals. The proportional
hazard assumption was satisfied for all outcomes evaluated.
A propensity score analysis was carried out using a nonpar-
simonious logistic regression model comparing patients split
by GP IIb/IIIa use. Multiple variables were included in the
model, including all variables with significant interactions.
Propensity Score Analysis. In order to investigate whether
or not any association of GP IIb/IIIa inhibitor use on
clinical outcomes was related to procedural risk, we created
a propensity score to assess the baseline risk of each patient
who underwent PCI. Multiple logistic regression with GP
IIb/IIIa use as the dependent variable was used to develop the
propensity score [12, 13]. All potential confounding variables
remained in the model regardless of level of statistical
significance on univariate analysis. The regression model
was then used to generate the predicted probability of GP
IIb/IIIa inhibitor use for each patient (i.e., their “propensity
score”), which ranged between 0 and 1. We then undertook
a regression adjustment incorporating the propensity score
into a proportional hazardmodel as a covariate.Weused SPSS
for Windows and Mac version 20 for all analyses.
3. Results
Of the 3047 patients, 1294 (42.5%) were treated with GP
IIb/IIIa inhibitors. Of the patients treated with GP IIb/IIIa
inhibitors, themajority 1,092 patients (84.4%) received abcix-
imab. 135 patients received tirofiban (10.4%) and 67 received
eptifibatide (5.18%). Follow-up was for a median of 4.6 years
(IQR range: 3.0–6.2 years).
3.1. Patient Characteristics (Table 1). Patients treated with
GP IIb/IIIa inhibitors were younger and more likely to be
smokers. They had fewer comorbidities, being significantly
less likely to have suffered a previous myocardial infarc-
tion (MI) or cerebrovascular accident (CVA), hypertension,
hypercholesterolaemia, renal disease, and peripheral vascular
disease (PVD). They were also less likely to have previously
undergone PCI.
3.2. Procedural Characteristics (Table 2). Patients treated
with GP IIb/IIIa inhibitors were significantly more likely
to undergo the procedure via the femoral route, receive
intervention of the LAD, and have multivessel intervention.
They were also more likely to undergo PCI with drug-eluting
stents and utilise a pressure wire prior to the PCI. Patients
receiving GP IIb/IIIa inhibitors were more likely to have a
successful angiographic result after PCI than those who did
not.
3.3. ProceduralOutcomes (Table 3). InhospitableMACE rates
were similar between those patients treated with GP IIb/IIIa
inhibitors and those who were not. However, patients treated
with GP IIb/IIIa inhibitors had higher rates of inhospitable
Q wave MI. The major bleeding rate and total bleeding rate
were significantly higher in the GP IIb/IIIa group, though the
minor bleeding rate was not significantly different.
3.4. Long-Term Outcomes
3.4.1. All-Cause Mortality (Figure 1). The unadjusted Kaplan-
Meier estimates of all-causemortality showed decreased rates
of mortality for patients treated with GP IIb/IIIa inhibitors
versus those who were not (𝑃 < 0.0001; Figure 1). Analysis
of specific GP IIb/IIIa inhibitors showed decreased mortality
associated with the use of abciximab (1,092 patients; 𝑃 <
0.001) and tirofiban (135 patients; 𝑃 = 0.003) versus no
GP IIb/IIIa inhibitor use. However, eptifibatide (67 patients)
showed a nonsignificant trend for decreased mortality (𝑃 =
0.110). There was no significant difference between agents.
3.4.2.MajorAdverse Cardiac Events (Figure 2). Kaplan-Meier
estimates showed decreased rates of MACE (𝑃 < 0.0001;
Figure 2) for patients treated with GP IIb/IIIa inhibitors
versus those not. There was no difference between the
different types of GP IIb/IIIa inhibitor.
3.4.3. The Cox Regression Analysis. The age-adjusted Cox
regression analysis showed a reduction in the hazard of
death (hazard ratio: 0.704; 95% confidence interval: 0.570–
0.868; 𝑃 = 0.001) and MACE (hazard ratio: 0.832; 95%
confidence interval: 0.699–0.992) for patients treatedwithGP
IIb/IIIa inhibitors. However, after multivariate adjustment
the benefits in survival (hazard ratio: 0.828; 95% confidence
interval: 0.646–1.061; 𝑃 = 0.136; Figure 3) did not persist.
Similarly, after multivariate analysis, GP IIb/IIIa inhibitor
use was not associated with a reduction in MACE (hazard
ratio: 0.949; 95% confidence interval: 0.773–1.164; 𝑃 = 0.614;
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Table 1: Baseline characteristics.
No GP IIb/IIIa inhibitor
used (𝑛 = 1753)
GP IIb/IIIa inhibitor
used (𝑛 = 1294)
Significance (𝑃)
Age 65.1 (±12.4) 62.0 (±12.2) <0.001∗
Gender (female) 501 (28.6%) 336 (26.0%) 0.119
Previous MI 577 (32.9%) 352 (27.2%) 0.001∗
Previous CABG 160 (9.12%) 94 (7.26%) 0.073
Previous PCI 336 (19.2%) 154 (11.9%) <0.001∗
Current smoker 417 (23.8%) 430 (33.2%) <0.001∗
Hypertension 1079 (61.6%) 700 (54.1%) <0.001∗
Hypercholesterolaemia 1044 (59.6%) 617 (47.4%) <0.001∗
DM 448 (25.6%) 315 (24.3%) 0.447
Renal disease 103 (5.88%) 36 (2.78%) <0.001∗
Previous CVA 63 (3.59%) 26 (2.01%) 0.012∗
PVD 82 (4.68%) 38 (2.94%) 0.014∗
Cardiogenic shock 20 (1.14%) 21 (1.62%) 0.269
∗
𝑃 value < 0.05.
Table 2: Procedural characteristics.
No GP IIb/IIIa inhibitor
used (𝑛 = 1753)
GP IIb/IIIa inhibitor
used (𝑛 = 1294)
Significance (𝑃)
Access route
Radial 691 (39.4%) 383 (29.6%) <0.001∗
Brachial 1 (0.06%) 2 (0.15%) 0.267
Femoral 1061 (60.5%) 909 (70.2%) <0.001∗
Target vessel(s)
Right coronary artery 633 (36.1%) 499 (38.6%) 0.172
Left main coronary artery 36 (2.05%) 38 (2.93%) 0.123
Left anterior descending artery 662 (37.8%) 690 (53.3%) <0.001∗
Left circumflex artery 496 (28.3%) 386 (38.3%) 0.374
Bypass graft 94 (5.36%) 68 (5.26%) 0.935
Multivessel disease 401 (22.9%) 312 (24.1%) 0.436
Multivessel intervention 347 (19.8%) 401 (31.0%) <0.001∗
Drug-eluting stent used 909 (51.9%) 757 (58.5%) <0.001∗
IVUS used 86 (4.91%) 56 (4.23%) 0.487
Pressure wire used 88 (5.02%) 14 (1.08%) <0.001∗
Success 1697 (96.8%) 1286 (99.4%) <0.001∗
∗
𝑃 value < 0.05.
Figure 4). All covariates in this multivariate model and their
hazard ratios (HRs) are shown in Figures 3 and 4. Significant
variables are emboldened.
3.4.4. Propensity Analysis. After correcting for propensity
score, there were no significant differences in mortality or
MACE rates between patients receiving and not receiving
GP IIb/IIIa inhibitors. The risk ratio associated with GP
IIb/IIIa use compared with GP IIb/IIIa inhibitor naive across
all quintiles of baseline risk was 1.10 (95% CI: 0.86–1.41) for
mortality and 1.14 (0.90–1.45) for MACE.
4. Discussion
This study, using data from a large PCI registry, is one of
the largest observational studies yet performed specifically
assessing the effect of GP IIb/IIIa receptor inhibitors on long-
term outcomes in patients undergoing PCI after NSTE-ACS
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Table 3: Procedural outcomes.
No GP IIb/IIIa inhibitor
used (𝑛 = 1753)
GP IIb/IIIa inhibitor
used (𝑛 = 1294) Significance (𝑃)
Inhospital
MACE 24 (1.37%) 22 (1.70%) 0.457
Death 13 (0.74%) 7 (0.54%) 0.651
Q wave MI 5 (0.29%) 12 (0.93%) 0.025∗
Reintervention PCI 5 (0.29%) 6 (0.46%) 0.543
Emergency CABG 3 (0.17%) 1 (0.08%) 0.641
Coronary dissection/perforation 25 (1.43%) 26 (2.01%) 0.253
CVA 2 (0.11%) 0 (0.00%) 0.511
Side branch occlusion 10 (0.57%) 9 (0.70%) 0.817
Major bleeding 6 (0.34%) 14 (1.08%) 0.021∗
Minor bleeding 36 (2.05%) 40 (3.09%) 0.078
Total bleeding 42 (2.40%) 54 (4.17%) 0.0063∗
Heart block requiring pacing 2 (0.11%) 1 (0.08%) 0.578
DC cardioversion 4 (0.23%) 2 (0.15%) 1.00
∗
𝑃 value < 0.05.
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Figure 1:The unadjusted Kaplan-Meier curves showing cumulative
incidence of all-cause mortality comparing patients treated with GP
IIb/IIIa inhibitors to those not treated with them. Mortality was
significantly improved amongst patients treated with GP IIb/IIIa
inhibitors (𝑃 < 0.0001).
with concomitant routine oral P2Y
12
inhibitor use. No sig-
nificant association was seen between GP IIb/IIIa inhibitor
use and either long-term mortality or long-term MACE
rates after correction for confounding variables. GP IIb/IIIa
inhibitor use was associated with an increased risk of major
bleeding.
There is a lack of long-term follow-up data for the
use of GP IIb/IIIa inhibitors in patients following PCI for
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Figure 2:The unadjusted Kaplan-Meier curves showing cumulative
incidence of long-term MACE comparing patients treated with GP
IIb/IIIa inhibitors to those not treated with them. MACE were
significantly improved amongst patients treated with GP IIb/IIIa
inhibitors (𝑃 < 0.0001).
NSTE-ACS with trials mainly having assessed short-term
effects even prior to routine oral P2Y
12
inhibitor blocker
use. A large meta-analysis of 29,570 patients showed a small
but significant reduction in death or MI at 30 days (odds
ratio: 0.91; 𝑃 = 0.02) in patients with NSTEMI/UA. This
meta-analysis included 6 trials: PRISM [14], PRISM-PLUS
[6], PARAGON A [15], PARAGON B [16], PURSUIT [5],
and GUSTO IV [17]. Of these, only PARAGON B showed
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Variable Comparator HR 95% CI
Age 1.060
Hypercholesterolaemia No hypercholesterolaemia 1.076
Previous MI No previous MI 1.510
Previous CABG No previous CABG 1.286
Previous PCI No previous PCI 1.172
Previous CVA No previous CVA 1.585
Peripheral vascular disease No PVD 1.065
Diabetes mellitus No DM 1.426
Renal disease No renal disease 2.698
Drug-eluting stent(s) used No drug-eluting stent(s) used 0.720
Successful result Unsuccessful result 0.838
GP IIb/IIIa inhibitor used No GP IIb/IIIa inhibitor used 0.828
0.000 1.000 2.000 3.000 4.000
Hazard ratio
1.048–1.072
0.850–1.363
1.175–1.942
0.907–1.824
0.866–1.584
1.022–2.458
0.699–1.623
1.112–1.828
1.893–3.847
0.569–0.913
0.438–1.601
0.646–1.061
Figure 3: The multivariate Cox regression analysis for hazard of death (survival). Multivariate analysis failed to show a significant
improvement in mortality with GP IIb/IIIa inhibitor use. In addition to increased patient age, a history of myocardial infarction (MI),
cerebrovascular accident (CVA), diabetes mellitus (DM), and renal disease remained significant predictors of increased mortality. Drug-
eluting stents continued to be associated with improved survival.
0.000 1.000 2.000 3.000 4.000
Hazard ratio
Variable Comparator HR 95% CI
Age 1.039
Hypertension No hypertension 1.004
Previous MI No previous MI 1.370
Previous CABG No previous CABG 1.298
Previous PCI No previous PCI 1.157
Previous CVA No previous CVA 1.443
Peripheral vascular disease No PVD 1.046
Diabetes mellitus No DM 1.433
Renal disease No renal disease 2.521
Multivessel disease No multivessel disease 1.190
Successful result Unsuccessful result 0.772
GP IIb/IIIa inhibitor used No GP IIb/IIIa inhibitor used 0.949
1.029–1.048
0.809–1.247
1.105–1.700
0.959–1.756
0.895–1.495
0.959–2.173
0.715–1.532
1.158–1.773
1.829–3.474
0.929–1.523
0.449–1.328
0.773–1.164
Figure 4: The multivariate Cox regression analysis for hazard of MACE. Multivariate analysis failed to show a significant decrease in the
hazard ofMACEwith GP IIb/IIIa inhibitor use. In addition to increased patient age, a history of myocardial infarction (MI), diabetes mellitus
(DM), and renal disease remained significant predictors of increased hazard of MACE.
a significant improvement on independent analysis at 30
days (odds ratio 0.58; 𝑃 = 0.04), and there was no
significant improvement in mortality. Clopidogrel, prasugrel,
and ticagrelor act upstream of GP IIb/IIIa mediated platelet
aggregation and all patients in our study received a loading
dose of 300 or 600mg clopidogrel. Our patients may there-
fore have benefitted less from the additional antiplatelet effect
of GP IIb/IIIa inhibitors.
More recently, ISAR-REACT 2 [7] included 2,022 “high
risk” NSTE-ACS patients treated with 500mg aspirin and
600mg clopidogrel prior to abciximab treatment. A subgroup
analysis of NSTEMI patients was performed. The composite
end point of death MI or urgent revascularisation was
reduced in NSTEMI patients (RR: 0.71; 95% CI: 0.54–0.95;
𝑃 = 0.02; 𝑃 = 0.07 for interaction). However, mortality
was not significantly reduced (RR: 0.69, 95% CI: 0.32–1.47,
𝑃 = 0.33) and by one-year follow-up this nonsignificant trend
had almost disappeared (RR: 0.91, 95%CI: 0.61–1.37,𝑃 = 0.66)
[8]. Interestingly, in contrast to our data, this study showed no
increased risk of major bleeding with these agents (RR: 1.00,
95% CI: 0.50–2.08).
GP IIb/IIIa inhibitors, through potent inhibition of
platelet aggregation, are thought to reduce periprocedural
thrombosis. This could be expected to reduce early recurrent
myocardial infarction, though any reductions in longer-
term mortality through such a mechanism may be much
smaller, explaining why no trials or meta-analyses have
shown a survival benefit from these agents. Furthermore, any
mortality benefit gained through reducing MI may be offset
by complications such as bleeding; indeed, our study showed
a significantly increased risk of both major bleeding and total
bleeding in those treated with GP IIb/IIIa inhibitors. This
finding is supported by evidence from registries indicating
that adverse events from these agents may be more common
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than indicated by trials [10]. However, there was a higher rate
of femoral access amongst the GP IIb/IIIa cohort, potentially
leading to increased bleeding risk.
In our study, patients receiving GP IIb/IIIa inhibitors
were younger and had fewer comorbidities suggesting under-
use of GP IIb/IIIa inhibitors in higher risk patients. Whilst
patients of varying age and comorbidity may be expected
to benefit equally from the potent-antiplatelet effects of
these agents during PCI for NSTEMI, there is evidence that
increasing age is an independent risk factor for bleeding fol-
lowing GP IIb/IIIa inhibitor use [18]. Furthermore, patients
with comorbidities are likely to be less tolerant of haem-
orrhage than younger, fitter patients. Indeed, one explana-
tion for the observation of higher postmarketing compli-
cations from these agents has been the increased use of
GP IIb/IIIa inhibitors in elderly patients; the average age of
patients whose deaths are directly attributable to GP IIb/IIIa
inhibitors in postmarketing surveillance is 69 years, com-
pared with 60 years across all patients in various randomised
trials [10].
It is possible that our results are influenced by our
choice of GP IIb/IIIa agents. However, our data fail to show
superiority for any single agent. Furthermore, the TARGET
trial showed abciximab to be superior to tirofiban at 30 days
[19]. Whilst higher doses of tirofiban may be more effective
[20, 21], the vast majority (84.4%) of our patients who
received GP IIb/IIIa inhibitor were administered abciximab.
We therefore feel it is unlikely that a possible benefit fromGP
IIb/IIIa inhibitors has been obscured through the use of less
effective agents.
5. Study Limitations
Our study is a consecutive but retrospective observational
analysis from a single center’s experience. As this was an
observational study the findings may have been subject to
confounding factors that we have been unable to control
for. This may include adherence to evidence-based therapies
after discharge, which is known to be associated with poor
outcomes. However, our dataset includes most major clinical
variables known to affect outcome, which would support the
validity of our results.
The inhospital mortality rates in this study are signif-
icantly lower (0.54% and 0.74% for those receiving and
not receiving GP IIb/IIIa inhibitors, resp.) than previously
reported in NSTEMI patients [22]. This may be at least
partially explained by the selective nature of our high-volume
cardiac centre. As our centre lacks an emergency department,
the cohort of patients it receives may differ from those seen
in general hospitals. It is therefore possible that our results
may not fully reflect the benefits and risks of GP IIb/IIIa
inhibitor use in a population of NSTEMI patients typically
encountered in other hospitals.
We were able to analyze only 92% of individuals who
had PCI during the study period due to incomplete datasets.
We cannot account for the effects of residual confounding or
of selection bias caused by exclusion of this 8% of patients.
However, this is unlikely as the distribution of GP IIb/IIIa
inhibitor use was the same in the excluded and analyzed
groups (data not shown). Finally although our multivariate
analysis revealed no improvement in survival for patients
treated with GP IIb/IIIa use, it is possible that we had
insufficient power to detect a difference in mortality.
6. Conclusion
Although GP IIb/IIIa inhibitor use appeared to be associated
with improved outcome after PCI for NSTEMI, patients
who received GP IIb/IIIa inhibitors had a different risk
profile to patients who did not receive GP IIb/IIIa inhibitors.
Therefore after multivariate adjustment including the use of a
propensity score, we observed no improvement in MACE or
survival in those patients who receivedGP IIb/IIIa inhibitors.
GP IIb/IIIa inhibitor usewas associatedwith an increased risk
of major and total bleeding.
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